Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells
Medical Research Center, Chungbuk National University, Cheongju, Korea. Archives of Pharmacal Research
(Impact Factor: 2.05).
11/2010; 33(11):1789-95. DOI: 10.1007/s12272-010-1111-7
Surgical resection of gastric cancer has made significant progress, but majority of patients with advanced gastric cancer face relapse and die within five years. In this study, the antitumor activity of ex vivo expanded T cells against the human gastric cancer was evaluated in vitro and in vivo. Human peripheral blood mononuclear cells were cultured with IL-2-containing medium in anti-CD3 antibody-coated flasks for 5 days, followed by incubation in IL-2-containing medium for 9 days. The resulting populations were mostly CD3(+) T cells (97%) and comprised 1% CD3⁻CD56(+), 36% CD3(+)CD56(+), 11% CD4(+), and 80% CD8(+). This heterogeneous cell population was also called cytokine-induced killer (CIK) cells. CIK cells strongly produced IFN-γ, moderately TNF-α, but not IL-2 and IL-4. At an effector-target cell ratio of 30:1, CIK cells destroyed 58% of MKN74 human gastric cancer cells, as measured by the ⁵¹Cr-release assay. In addition, CIK cells at doses of 3 and 10 million cells per mouse inhibited 58% and 78% of MKN74 tumor growth in nude mouse xenograft assays, respectively. This study suggests that CIK cells may be used as an adoptive immunotherapy for gastric cancer patients.
Available from: ocean.kisti.re.kr
- "It could directly kill tumor cells, adjust and enhance immune function, withnot damaging the structure and functions of the immune system. Its effects on the treatment of malignant solid tumors has been widely recognized (Blattman and Greenberg, 2004; Kim et al., 2010). But there is rarely reports on the analysis of the effects of regulation and maintaining time of cellular immune function in patients with lung cancer by CIK cell therapy, thus the author summarized and analyzed the experience of extracting the mononuclear cells (PMBC) to prepare CIK cells from the peripheral blood of patients with lung cancer, and the clinical efficacy data of prepared CIK cells reinfusion, reported as the following. "
[Show abstract] [Hide abstract]
To study the CIK cell treatment effects on regulation of cellular immune function disorders in patients with lung cancer, and to analyze the time characteristics.
Cellular immune function was assessed by FCM, and patients with functional disorders were randomly divided into two groups, one given CIK cell therapy within 18 months (5 courses) and the other the controls, which were followed up for 1 year with cellular immune functions tested once a month.
There were 5 types of cellular immunity, 4 of which are disorders; after CIK treatment, the improvement rate of the 4 groups were 79.1%, 70.8%, 76.0% and 70.0%, intergroup differences not being statistically significant (P=0.675), all significantly higher than in the control group (P=0.000). The median maintenance times for the 4 groups were 10.4 months (9.76-11.04), 8.4 months (7.86-8.94), 9.8 months (9.20-10.4) and 7.9 months (6.25-9.55), respectively.
CIK cells were able to improve the immune functions of patients with lung cancer, the rate of improvement and maintenance time being related to the immune function before the treatment and CIK-cell-therapy courses.
Asian Pacific journal of cancer prevention: APJCP 06/2013; 14(6):3587-92. DOI:10.7314/APJCP.2013.14.6.3587 · 2.51 Impact Factor
Available from: Chiara Della Bella
- "Recently, Kim and coll.  evaluated the antitumor activity of ex vivo expanded T cells against human GC. For this purpose, human peripheral blood mononuclear cells were cultured with IL-2-containing medium in anti-CD3 antibody-coated flasks for 5 days, followed by incubation in IL-2-containing medium for 9 days. "
[Show abstract] [Hide abstract]
ABSTRACT: Gastric cancer is the second cause of cancer-related deaths worldwide.
is the major risk factor for gastric cancer. As for any type of cancer, T cells are crucial for recognition and elimination of gastric tumor cells. Unfortunately T cells, instead of protecting from the onset of cancer, can contribute to oncogenesis. Herein we review the different types, “friend or foe”, of T-cell response in gastric cancer.
Clinical and Developmental Immunology 05/2012; 2012(16):690571. DOI:10.1155/2012/690571 · 2.93 Impact Factor
Archives of Pharmacal Research 11/2010; 33(11):1699-701. DOI:10.1007/s12272-010-1100-x · 2.05 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.